Changchun High-tech: Baike Biotechnology's influenza virus split vaccine clinical trial application approved.

Changchun High-tech announced that its subsidiary Baik Biological has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for Baik Biological's influenza virus split vaccine has been approved. The vaccine is intended for individuals aged 60 and above to prevent influenza caused by the influenza virus. If the vaccine can be successfully developed, it will further improve Baik Biological's influenza vaccine development pipeline, providing new vaccination options for individuals aged 60 and above, and expanding the population coverage of Baik Biological's influenza vaccine.